First Long Island Investors LLC Purchases 137,555 Shares of Zoetis Inc. $ZTS

Key Points

• First Long Island Investors LLC increased its stake in Zoetis Inc. by 402.9%, owning 171,698 shares worth approximately $28.27 million.
• Zoetis reported $1.76 earnings per share for the latest quarter, exceeding analyst expectations of $1.62, with a revenue of $2.46 billion showing a 4.2% year-on-year increase.
• Analysts have mixed ratings for Zoetis, with five maintaining a buy rating and four a hold rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $200.88.

First Long Island Investors LLC boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 402.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,698 shares of the company's stock after purchasing an additional 137,555 shares during the period. Zoetis comprises about 2.3% of First Long Island Investors LLC's holdings, making the stock its 15th largest holding. First Long Island Investors LLC's holdings in Zoetis were worth $28,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Nova Wealth Management Inc. acquired a new position in Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC acquired a new position in Zoetis in the 1st quarter valued at approximately $27,000. Saudi Central Bank acquired a new position in Zoetis in the 1st quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.5%

NYSE ZTS traded down $2.28 on Friday, hitting $148.33. 3,111,229 shares of the company were exchanged, compared to its average volume of 2,249,190. The company has a market cap of $65.74 billion, a PE ratio of 25.53, a PEG ratio of 2.38 and a beta of 0.88. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The stock has a fifty day moving average of $152.32 and a 200-day moving average of $157.21. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis's revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Finally, Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Zoetis currently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.